10:06 AM EST - Odyssey Group International Inc : Today presents a Company update and recap of its concussion drug development program. Concussions represent an ‘unmet’ medical need and affect tens of millions worldwide. Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021. Since the acquisition, Odyssey has added key industry experts to its management, made significant progress in the drug development program, and completed a Phase I human clinical trial. Odyssey Group International Inc
shares O.ODYY are trading unchanged at $0.16.
